Shots:

• The P-Ib MAD trial involves assessing IMT-002 (350 /1050 mg- qd/bid over a 2wks.) vs PBO in 30 T1D patients preselected for HLA-DQ8 aged b/w 18-45yrs. and were interspersed in the 4 groups and involves a 1wk. follow-up after dose completion
• The therapy was safe & well-tolerated with no SAEs & did not increase with dose. PK were followed for (1050mg- qd) & (350/700/1050mg- bid) over 24-hrs. after drug administration- IMT-002 (bid regimen) showed increase in Cmax & high Ctrough @4hrs. while qd dose showed low Cmax & Ctrough
• IMT-002 targets HLA-DQ8 to prevent the immune system from attacking insulin-producing beta cells. The company is planning to advance the therapy in the P-II study

| Ref: Businesswire | Image: IM Therapeutics